A method for constructing an iPSC cell line with ARHGAP11B gene deletion and its application
The CRISPR/Cas9 system combined with specific sgRNA to knock out the ARHGAP11B gene in iPSC cells was constructed, which solved the problem of difficulty in constructing such cell lines in the prior art and achieved efficient and thorough gene editing , provides an in vitro model for in-depth study of ARHGAP11B function.
Patent Information
- Application Number
- CN202210183615.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-02-25
AI Technical Summary
There has been no report on the construction of induced pluripotent stem cells (iPSCs) with the deletion of ARHGAP11B gene, and it is difficult to deeply explore the specific functions and functions of ARHGAP11B gene.
The CRISPR/Cas9 system was used to bind specific sgRNA to target knockout the human ARHGAP11B gene to construct an iPSC cell line with ARHGAP11B gene deletion. The CRISPR/Cas9 vector included specific sgRNA and resistance gene Puromycin N-acetyl-transferase and GFP fluorescence Protein, improves gene editing efficiency through puromycin screening and electroporation transfection.
It realizes efficient knockout of ARHGAP11B gene, is simple to operate and thoroughly effective, improves the efficiency of CRISPR/Cas9 genome editing technology in iPSC cells, and provides an in vitro model for in-depth study of the function of ARHGAP11B gene.
Smart Images

Figure CN114457080B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cell genetic engineering, and in particular to a construction method and application of an iPSC cell line with ARHGAP11B gene deletion. Background Art
[0002] Mammals have a highly developed cerebral cortex. The newly developed cerebral cortex plays an important role in regulating functions. Although the subcortical brain and spinal cord have also developed, they are subordinate to the cerebral cortex in terms of function. The cerebral cortex is the highest-level center for regulating or controlling body movements. The human cerebral cortex has made a new leap, with the ability of abstract thinking, becoming the material basis of conscious activities. The cerebral cortex plays a vital role in memory, attention, thinking, language, consciousness, perception, etc. Therefore, it can be said that the cerebral cortex is equivalent to the "headquarters" of the human body. Therefore, the study of factors that affect the development of the cerebral cortex has also become a hot topic in life science research.
[0003] Certain specific aspects of the expansion of the human neocortex are thought to involve human-specific genomic changes. Recent transcriptomic studies have determined that certain previously identified human-specific genes are preferentially expressed in neural progenitors and have implicated these genes in the expansion of the human neocortex. Of these genes, the one most specifically expressed in human bRGs compared to neurons is ARHGAP11B. ARHGAP11B evolved after the human lineage diverged from the chimpanzee lineage as a product of a partial gene duplication of ARHGAP11A, the gene encoding a Rho GTPase-activating protein. Forced expression of ARHGAP11B in the neocortex of embryonic mice results in an increase in BP (basal progenitor) proliferation and size.
[0004] Induced pluripotent stem cells (iPSCs) technology is a major breakthrough in the field of stem cell research. It avoids the long-standing ethical controversy, solves the problem of immune rejection in stem cell transplantation medicine, and makes a big step forward in the clinical application of stem cells. With the continuous development of iPS technology and the continuous updating of technical level, its advantages in basic research in life sciences and medicine have become increasingly obvious. The cell model established by combining induced pluripotent stem cells and genome editing technology provides a unique experimental platform for disease research. Using this platform system, researchers can study the effects of specific gene mutations and even chromosome structural variations on the functions of various human cell types and tissues and organs and their detailed molecular mechanisms, and establish "personalized" disease models carrying different genetic mutations for large-scale drug screening.
[0005] By using CRISPR / Cas9 technology to establish an iPSC cell line with ARHGAP11B gene deletion and observe the effect of ARHGAP11B gene deletion on iPSC, it is expected that an in vitro model of transgenic ARHGAP11B will be established to further explore the specific functions and effects of the ARHGAP11B gene.
[0006] So far, there has been no report on the construction of ARHGAP11B gene knockout in induced pluripotent stem cells. Summary of the invention
[0007] The purpose of the present invention is to overcome the shortcomings of the above-mentioned prior art and provide a method for constructing an iPSC cell line with ARHGAP11B gene deletion and its application. Among them, the specific sgRNA provided by the present invention can efficiently target the human ARHGAP11B gene, and a method for knocking out the ARHGAP11B gene in the iPSC cell line is constructed based on the CRISPR / Cas9 system. The method is simple to operate and the knockout effect is more thorough.
[0008] To achieve the above object, the technical solution adopted by the present invention is:
[0009] In a first aspect, the present invention provides a specific sgRNA for targeted knockout of the human ARHGAP11B gene, wherein the targeting site of the sgRNA in the human ARHGAP11B gene is located on exon 6 of the human ARHGAP11B gene; and the nucleotide sequence corresponding to the sgRNA is at least one of the following:
[0010] a) sgRNA1:
[0011] gcgtgtaccagactttatcc;
[0012] b) sgRNA2:
[0013] ggaaaagataccagccatgt;
[0014] c) sgRNA3:
[0015] gactttatcctggaaaagat.
[0016] In a second aspect, the present invention provides a CRISPR / Cas9 vector, wherein the CRISPR / Cas9 vector comprises the above-mentioned specific sgRNA for targeted knockout of the human ARHGAP11B gene. More specifically, the CRISPR / Cas9 vector comprises at least one of sgRNA1, sgRNA2, and sgRNA3.
[0017] More preferably, the concentration of the CRISPR / Cas9 vector is 1255 ng / μl.
[0018] As a preferred embodiment of the CRISPR / Cas9 vector of the present invention, the CRISPR / Cas9 vector is digested by plasmid px458-exon6 and plasmid pCEP4-middle, and then carries the above-mentioned specific sgRNA for targeted knockout of the human ARHGAP11B gene, the resistance gene Puro and the GFP fluorescent protein gene.
[0019] In a third aspect, the present invention provides a host cell comprising the above-mentioned CRISPR / Cas9 vector.
[0020] In a fourth aspect, the present invention provides a construction method for knocking out the ARHGAP11B gene in an iPSC cell line based on the CRISPR / Cas9 system, comprising the following steps:
[0021] S1. Transfect iPSCs with the above CRISPR / Cas9 vector, culture them, and screen the successfully transfected positive iPSCs with puromycin;
[0022] S2. Identify the pluripotency of successfully transfected positive iPSCs.
[0023] The sequencing results and the identification of the pluripotency of the iPSC cell line proved that the iPSC cell line lacking the ARHGAP11B gene was successfully constructed.
[0024] As a preferred embodiment of the method for constructing the ARHGAP11B gene knockout in the iPSC cell line based on the CRISPR / Cas9 system of the present invention, the transfection in step S1 is performed by electroporation using the BEX CUY2 EDITⅡ transfection system.
[0025] As a preferred embodiment of the construction method of knocking out the ARHGAP11B gene in the iPSC cell line based on the CRISPR / Cas9 system of the present invention, after the transfection in step S1, the iPSC is added to the mTeSRTM1 medium containing Y-27632 (5mM 2000×) for culture. After transfection, the iPSC cells are cultured in the mTeSRTM1 medium containing Y-27632, which improves the survival ability and clone formation ability of the iPSC cells.
[0026] As a preferred embodiment of the construction method for knocking out the ARHGAP11B gene in the iPSC cell line based on the CRISPR / Cas9 system of the present invention, the construction method also includes the step of PCR identification of positive iPSCs, and the primers in the PCR identification are shown in SEQ ID NOs: 5 to 6.
[0027] In a fifth aspect, the present invention provides an iPSC cell line obtained by the above-mentioned construction method. The present invention also provides the use of the iPSC cell line in establishing an in vitro cell model of ARHGAP11B gene knockout, so as to further explore the specific functions and effects of the ARHGAP11B gene.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] 1) The present invention utilizes the CRISPR / Cas9 system to knock out the human ARHGAP11B gene from the iPSC cell line, which is easy to operate and has a complete and thorough effect. By modifying and optimizing the CRISPR / Cas9 genome editing technology, the resistance gene Puromycin N-acetyl-transferase and GFP fluorescent protein are co-expressed on the vector, and the iPSC cells after gene editing are screened by puromycin, which can greatly improve the gene editing efficiency of the CRISPR / Cas9 genome editing technology in iPSC cells, and the GFP fluorescent protein can be used to directly judge the knockout of the ARHGAP11B gene. Compared with chemical or virus-mediated transfection methods, the present invention uses electroporation for transfection, which greatly improves the transfection efficiency; the optimized CRISPR / Cas9 genome editing technology is easy to operate, shortens the time, and improves the efficiency, providing a powerful tool for future stem cell genome editing;
[0030] 2) The method of knocking out the ARHGAP11B gene based on the CRISPR / Cas9 system in the present invention has a more thorough knockout effect compared with silencing, knockdown, interference and other methods;
[0031] 3) The present invention can prove that the iPSC cell line lacking the ARHGAP11B gene was successfully constructed based on the sequencing results and the pluripotency identification of the iPSC cell line. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 The sequence diagram of three sgRNAs on the ARHGAP11B gene of the present invention;
[0033] Figure 2 This is a schematic diagram of the pCEP4-Cas9-EGFP-11B-exon6-3gRNA expression vector of the present invention;
[0034] Figure 3 This is a diagram showing the sequencing results of the pCEP4-Cas9-EGFP-11B-exon6-3gRNA expression vector of the present invention;
[0035] Figure 4 This is the mycoplasma detection diagram of iPSC cell line;
[0036] Figure 5 This is a microscopic observation of positive cells expressing GFP fluorescent protein after puromycin selection;
[0037] Figure 6 This is the electrophoresis identification diagram of the iPSC cell line with ARHGAP11B gene deletion (M is 2000 Marker, WT is the positive control);
[0038] Figure 7 This is the genotype sequencing result of the iPSC cell line with ARHGAP11B gene deletion;
[0039] Figure 8 This is a diagram for detecting the integration of foreign genes;
[0040] Fig. 9 This is the off-target analysis diagram;
[0041] Fig.10 This is the result of cell immunofluorescence;
[0042] Fig.11 This is the karyotype analysis diagram of the positive clone iPSC63 cells;
[0043] Fig.12 This is the qPCR quantitative analysis diagram of positive clone iPSC63 cells;
[0044] Fig.13 This is a diagram of the three-germ layer differentiation of the positive clone iPSC63 cells. DETAILED DESCRIPTION
[0045] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0046] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.
[0047] Example 1: A method for knocking out the ARHGAP11B gene in iPSC cell lines based on the CRISPR / Cas9 system
[0048] 1. sgRNA design
[0049] "sgRNA", or Single guide RNA, can identify specific genomic fragments during CRISPR / Cas9 gene editing (including gene knockout). According to the sgRNA target sequence design principle, the target sequence was designed in exon 6 of the human ARHGAP11B gene (the nucleotide sequence is shown in SEQ ID No. 1), and three sgRNAs were constructed, namely sgRNA1, sgRNA2 and sgRNA3, whose nucleotide sequences are shown in SEQ ID No. 2 to 4 (see Table 1). The sequence diagrams of the three sgRNAs are shown in Figure 1 shown.
[0050] Table 1
[0051] sgRNA ID Nucleotide sequence sgRNA1 gcgtgtaccagactttatcc sgRNA2 ggaaaagataccagccatgt sgRNA3 gactttatcctggaaaagat
[0052] 2. Construction of CRISPR / Cas9 vector
[0053] The three sgRNAs were annealed to form dimers, and the double-stranded sgRNA of the oligonucleotide annealing product was connected to the px458 vector exon after BbS I digestion using T4 polynucleotide kinase to obtain px458-exon6-3gRNA. Then, px458-exon6-3sgRNA and pCEP4-middle were double-digested with PciⅠ and NotⅠ, and 6898bp and 6910bp fragments were recovered by gel running, respectively. After gel cutting and recovery, they were connected with solutionⅠ at 16℃ for 2 hours. After transformation, single clones were picked for restriction digestion identification and sequencing identification, thereby obtaining pCEP4-Cas9-EGFP-11B-exon6-3gRNA expression vector (schematic diagram is shown in Figure 2 ), the constructed pCEP4-Cas9-EGFP-11B-exon6-3gRNA expression vector was digested and identified, and the plasmid with the correct digestion was sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing identification. The sequencing results showed that the plasmid sequences were correct (sequencing results see Figure 3 ). The plasmid with the correct sequencing was selected and digested with FseⅠ endonuclease. The digestion product was purified and recovered for later use. PCR was performed with primers T2A-puro-F / R using px459 as a template. After gel purification and recovery, the product was recombined with the above digestion purification and recovery product using recombinase. After transformation, a single clone was selected for sequencing identification. The constructed pCEP4-Cas9-puro-EGFP-11b-exon6-3gRNA expression vector was 14510 bp in total. Two plasmids were randomly selected and sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing identification. The sequencing results showed that both clones were correct. The correct plasmid was selected and extracted with an endotoxin-free mini-prep kit and frozen at -20 degrees for later use.
[0054] 3. Construction of iPSC cell line with ARHGAP11B gene deletion
[0055] (1) Pre-thaw iPSC cells and prepare for transfection. The cell transfection steps are as follows:
[0056] 1) Collect iPSC cells with a cell density of 80%.
[0057] 2) Aspirate the culture medium (6-well plate), wash twice with PBS, and add 1 mL of ACCUTASE TM , incubate at 37°C for approximately 4 minutes.
[0058] 3) Add 1 mL of DPBS to stop digestion, mix well by pipetting, and transfer to a 15 mL centrifuge tube. Add 1 mL of DPBS to each well to collect the remaining cells, and also transfer to a 15 mL centrifuge tube.
[0059] 4) Centrifuge at 200g, 25°C for 5 minutes.
[0060] 5) Aspirate and discard the supernatant, being careful not to touch the cell pellet.
[0061] 6) Add 1 mL of OPTI-MEM to resuspend the cells, centrifuge at 200 g, 25°C for 5 minutes, and discard the supernatant.
[0062] 7) Add 1 mL of OPTI-MEM and fully resuspend the cells.
[0063] 8) Use the transfection system (BEX CUY2 EDITⅡ) for electroporation. First, aspirate 10uL of suspended cells and put them into the electroporation cup. The test resistance is 262 ohms. Then aspirate 10μl of suspended cells, 4μl pCEP4-Cas9-puro-EGFP-11b-exon6-3gRNA plasmid (1255ng / μl), and 9uLOPTI-MEM. Mix well and add to the electroporation cup. No bubbles should be present.
[0064] 9) Set the electroporation conditions as shown in Table 2 below:
[0065] Table 2
[0066]
[0067] 10) Click the start button. After completion, remove the electroporation cup and aspirate the cells into a 6-well plate pre-coated with Matrigel matrix (suspended in the air, do not let the pipette touch the liquid surface). Add 2 ml of mTeSR containing Y-27632 to each well. TM 1 (Basal Medium) culture medium.
[0068] 11) Place the culture plate in an incubator at 37°C and 5% CO2.
[0069] 12) Since the activity of cells just electroporated is weak, puromycin is used for screening after one week of culture. During the screening process, the GFP fluorescent protein carried by the cells can be observed under a fluorescence microscope to determine the proportion of positive cells ( Figure 4 ) for single clone selection.
[0070] (2) Monoclonal selection:
[0071] 1) One week later, 1 μg / mL puromycin was added to select positive cells. After the selected cells grew to 70-80% confluence, ACCUTASE was added. TM Incubate at 37°C for approximately 4 minutes.
[0072] 2) Add 1 mL of DPBS to stop digestion, mix well by pipetting, and transfer to a 15 mL centrifuge tube. Add 1 mL of DPBS to collect the remaining cells, and also transfer to a 15 mL centrifuge tube.
[0073] 3) Centrifuge at 200g, 25℃ for 5 minutes and discard the supernatant, being careful not to touch the cell pellet.
[0074] 4) Use 1 mL of mTeSR containing Y-27632 TM Resuspend the cells in 1% culture medium and passage 500 cells per well in a 10 cm dish (pre-coated with Matrigel).
[0075] 5) On the first day of cell passage, use mTeSR containing Y-27632 TM 1 medium to increase single cell survival and clone formation rate, and then use mTeSR without Y-27632 every day TM 1. Change the culture medium. Single clone selection can be performed after one week of cell culture.
[0076] 6) Before selecting clones, first add 0.5 ml of mTeSR to each well of a 48-well plate coated with Matrigel. TM 1 culture medium.
[0077] 7) In a clean bench, under a microscope, use a 20 μl pipette to scrape clones. Half of the clones are used for genotyping and the other half are used for culture.
[0078] (3) Mycoplasma detection of iPSC cell lines:
[0079] 1) When the cells have been passaged or the medium has been changed for more than three days and the confluence has reached 80%, take 50 μl of the culture supernatant and place it in a microcentrifuge tube for later use.
[0080] 2) Take MycoBlue Buffer out of the -20℃ freezer, wait for it to thaw, and mix thoroughly by inverting. Prepare the following reaction system in a microcentrifuge tube according to the number of samples to be tested:
[0081] Table 3
[0082] Components Single reaction volume (μl) MycoBlue Buffer 24 MycoBlue Enzyme 1
[0083] 3) Sample addition: Sample: Add 1 μl of the culture supernatant to be tested into 25 μl of the reaction system;
[0084] Positive control: add 1 μl Positive Control to 25 μl reaction system;
[0085] Negative control: No sample was added to the 25 μl reaction system.
[0086] 4) Reaction: Place the reaction tube in the PCR instrument, set the temperature to 60°C, and incubate for 60 minutes. After the reaction is completed, observe the color of the reaction solution in a well-lit environment (with white paper as the background). If the reaction solution is still purple, it is determined to be mycoplasma negative; if the reaction solution turns sky blue, it is determined to be mycoplasma positive.
[0087] The test results showed that sample iPSC63 was negative, indicating that there was no mycoplasma infection. Figure 5 .
[0088] (4) Cell genome extraction: The remaining cells were processed into a cell suspension, centrifuged at 200 g for 5 minutes, the supernatant was discarded, 8 μl of NP40 lysis buffer was added, vortexed and mixed, and then placed in a PCR instrument. The PCR reaction conditions were: 56°C for 1 hour, 95°C for 10 minutes.
[0089] (5) PCR identification of target sites: On the ARHGAP11B gene, the sequences of primers exon6-F and exon6-R were designed as follows.
[0090] exon6-F:5'-atattactgacctcaccccc-3'(SEQ ID NO:5)
[0091] exon6-R:5'-ggtgcttaaagcacagctgg-3'(SEQ ID NO:6)
[0092] Use Ex Taq (2X) enzyme to prepare 20 μl PCR system as shown in the following table:
[0093] Table 4
[0094] Reagents Usage Ex Taq(2x) 10μl exon6-F 0.8μl exon6-R 0.8μl DNA template 0.2μl Sterilized water 8.2μl
[0095] PCR reaction conditions:
[0096] Table 5
[0097] temperature time 98℃ 1min 98℃ 15s 58℃ 30s 72℃ (return to step 2, cycle 30 times) 90s 72℃ 2min
[0098] The PCR products whose amplified fragment size meets the expected value are sent for sequencing. Figure 6 .
[0099] (6) Genotype identification of the target site: The PCR product was sent for Sanger sequencing, and the sequencing results were compared with the wild-type (primers as above: exon6-F and exon6-R) PCR sequence. It was determined that the iPSC63 cells were mutants with a deletion of 6 bp and an insertion of 1 bp. The results are shown in Figure 7 .
[0100] (7) After identification, the positive clone iPSC63 was expanded and cultured.
[0101] (8) Detection of exogenous gene integration: For the exogenous expression vector pCEP4-Cas9-puro-EGFP-11b-exon6-3gRNA, the primers EBNA1-F and EBNA1-R were designed as follows.
[0102] EBNA1-F: 5'-tgtctgacagcgaccatgaa-3' (SEQ ID NO:7)
[0103] EBNA1-R: 5'-aaatacaccaacagcacgca-3' (SEQ ID NO: 8)
[0104] Use Ex Taq (2X) enzyme to prepare 10 μl PCR system as shown in the following table:
[0105] Table 6
[0106] Reagents Usage Ex Taq(2x) 5μl EBNA1-F 0.4μl EBNA1-R 0.4μl iPSC63 genomic DNA / water / plasmid 0.1μl Sterilized water 4.1μl
[0107] PCR reaction conditions:
[0108] Table 7
[0109] temperature time 98℃ 1min 98℃ 15s 58℃ 30s 72℃ (return to step 2, cycle 30 times) 90s 72℃ 2min
[0110] Water and pCEP4-Cas9-puro-EGFP-11b-exon6-3gRNA plasmid were used as negative and positive controls, respectively. The reaction products were identified by gel electrophoresis. It can be seen that the positive control has obvious bands, while the sample iPSC63 has no bands like the negative control, indicating that the exogenous gene has not been integrated into the genome. Figure 8 .
[0111] (9) Off-target analysis: The top 10 off-target sites were obtained using Cas-OFFinder analysis. The site information is as follows.
[0112] Table 8
[0113] Off-target site number sequence OT1 AGAGAAGAGACCAGCCATGTGGG OT2 TGAAAAGACACCTGCCATGTGGG OT3 GAAAAAGATACCTTCCATGTGGG OT4 GGCAAGGAAACCAGCCATGTGGG OT5 ACATGGAGGGTATCTCTTCCAGG OT6 ACATGGCAGGTGGCTTTTCCAGG OT7 GGAAAAGATTGCAGTCATGTAGG OT8 ACATGGCTGGTGTCTTTATAAGG OT9 ACATGACTGGTATCTTTATTAGG OT10 AAAAGAGATCCCAGCCATGTGGG
[0114] Ten pairs of primer sequences were designed for these 10 potential off-target sites as follows.
[0115] Primer1-F:5'-GGAGGATGCTACAAACAAAG-3'(SEQ ID NO:9)
[0116] Primer1-R: 5'-CCCAAAAACATATGTTCACA-3' (SEQ ID NO: 10)
[0117] Primer2-F: 5'-AACAAAGCTAAATTCAAGGC-3' (SEQ ID NO: 11)
[0118] Primer2-R: 5'-ACAAAGGATCACAGCATTAT-3' (SEQ ID NO: 12)
[0119] Primer3-F: 5'-GATTACAGTGTGCCTTTCAT-3' (SEQ ID NO: 13)
[0120] Primer3-R: 5'-ACACAGTTCAGACAAAAGCC-3' (SEQ ID NO: 14)
[0121] Primer4-F: 5'-GTCAAGTCATGACAAATACG-3' (SEQ ID NO: 15)
[0122] Primer4-R: 5'-GGTTATCAAACATGCCAAAC-3' (SEQ ID NO:16)
[0123] Primer5-F: 5'-AGATTTCAATAAGCAGGCTC-3' (SEQ ID NO: 17)
[0124] Primer5-R: 5'-AAACAAAGACACCTGGAAGA-3' (SEQ ID NO:18)
[0125] Primer6-F: 5'-TGCTCTTATTCTTCTCCTTC-3' (SEQ ID NO: 19)
[0126] Primer6-R: 5'-TTGCACCTCACTAAACCTGA-3' (SEQ ID NO: 20)
[0127] Primer7-F: 5'-ATGTTAGTATCTGTCTCCCT-3' (SEQ ID NO: 21)
[0128] Primer7-R: 5'-AGGAACCACAAAACCATGCT-3' (SEQ ID NO: 22)
[0129] Primer8-F: 5'-GATGACTGTCTTCTTGCTGT-3' (SEQ ID NO: 23)
[0130] Primer8-R: 5'-GCCATGATTATCAACGTAGA-3' (SEQ ID NO: 24)
[0131] Primer9-F: 5'-CCTCAGAAAGTGACCTATTT-3' (SEQ ID NO: 25)
[0132] Primer9-R: 5'-ATGCCCTTCACATGGCTTT-3' (SEQ ID NO: 26)
[0133] Primer10-F:5'-AATTACCGAGTCTTGGGTAT-3'(SEQ ID NO:27)
[0134] Primer10-R: 5'-AGTCAAGTTCTGGTGAAGAT-3' (SEQ ID NO: 28)
[0135] Use Ex Taq (2X) enzyme to prepare 20 μl PCR system as shown in the following table:
[0136] Table 9
[0137] Reagents Usage Ex Taq(2x) 10μl Primer-F 0.8μl Primer-R 0.8μl iPSC63 genomic DNA 0.2μl Sterilized water 8.2μl
[0138] PCR reaction conditions:
[0139] Table 10
[0140] temperature time 98℃ 1min 98℃ 15s 58℃ 30s 72℃ (return to step 2, cycle 30 times) 90s 72℃ 2min
[0141] The PCR products whose amplified fragment size was in line with the expected size were sent for Sanger sequencing. The sequencing results showed that all 10 sites were wild-type and had not mutated, indicating that no off-target sites had occurred. Fig. 9 .
[0142] Example 2: Analysis of pluripotency identification of iPSC cell lines with ARHGAP11B gene deletion
[0143] (1) Cell immunofluorescence
[0144] The cells (iPSC63, wild-type WT iPSC) were passaged into three wells of a four-well plate, and the immunofluorescence experiment was started after the cell density reached 70%-80%.
[0145] 1) Aspirate the culture medium in the four-well plate and wash with PBS three times, 10 min each time;
[0146] 2) Fix the cells with 4% paraformaldehyde for 20 min and wash with PBS three times, 10 min each time;
[0147] 3) Add 0.5% Trition X-100 (prepared in PBS) and permeabilize for 20 min at room temperature, then wash with PBS three times, 10 min each time;
[0148] 4) Aspirate PBS, add normal goat serum, and block at room temperature for 30 minutes;
[0149] 5) Aspirate the blocking solution, add 200 μl of diluted primary antibody (Oct4, Sox2, Nanog) directly to each well, and incubate at 4°C overnight;
[0150] 6) Aspirate the primary antibody and wash with PBS three times, 10 min each time;
[0151] 7) Aspirate PBS, add the corresponding diluted fluorescent secondary antibody, and incubate with tin foil at room temperature for 30 minutes;
[0152] 8) Aspirate the secondary antibody and wash with PBS three times, 10 min each time (after adding the secondary antibody, all subsequent steps should be carried out in the dark);
[0153] 9) Add diluted DAPI to each well and incubate in the dark for 5 minutes to stain the nucleus of the cells, then wash with PBS 4 times, 10 minutes each time;
[0154] 10) Replace the PBS in each well and observe and take pictures under a fluorescence microscope.
[0155] The immunofluorescence results of the cells showed that the three pluripotency markers OCT4, SOX2 and NANOG were all expressed normally (reference Fig.10), indicating that iPSC63 cells are pluripotent.
[0156] (2) Karyotype analysis of positive clones
[0157] The cells in the two 6-well plates with a cell volume of more than 80% were digested and placed in a 15 mL centrifuge tube. After centrifugation, the supernatant was aspirated and 1 mL of culture medium was added to resuspend the cells. The culture medium was then filled to the top and sent to Foshan Dian Medical Testing Laboratory Co., Ltd. for karyotype analysis. The results showed that the iPSC63 cells had a normal karyotype (46.XX) (reference Fig.11 ).
[0158] (3) qPCR quantitative analysis
[0159] 1) Digest about 80% of the cells in a 6-well plate (iPSC No. 63, wild-type WT iPSC), centrifuge and remove the supernatant, add 1 mL of lysis buffer and mix well;
[0160] 2) Place the treated cells at room temperature for 5 minutes to allow the nucleic acid-protein complex to completely separate;
[0161] 3) Add 0.2 mL of chloroform to the cells, cover the tube, shake vigorously for 15 seconds, and leave at room temperature for 5 minutes;
[0162] 4) Centrifuge at 4°C, 12,000 rpm for 10 min; RNA is mainly in the upper colorless aqueous phase, transfer the aqueous phase to a new tube;
[0163] 5) Pretreatment of adsorption column: add 500 μl of column washing solution to the adsorption column, place at room temperature for 2 min, centrifuge at 12000 rpm at 4°C for 2 min, and discard the waste liquid;
[0164] 6) Add 200 μl of anhydrous ethanol to the supernatant collected in step 4, mix well, add to the adsorption column and let stand for 2 min, centrifuge at 4°C and 12000 rpm for 2 min, and discard the waste liquid;
[0165] 7) Add 600 μl of rinse solution to the adsorption column, centrifuge at 12000 rpm for 2 min at 4°C, and discard the waste solution;
[0166] 8) Repeat step 7);
[0167] 9) Centrifuge at 12000 rpm for 2 min, discard the collection tube, and place the adsorption column at room temperature for 5 min to remove the residual rinse solution in the adsorption column;
[0168] 10) Place the adsorption column in a new tube, add 50 μl RNase free ddH2O to the center of the membrane, leave at room temperature for 5 minutes, and centrifuge at 12000 rpm for 2 minutes to obtain RNA;
[0169] 11) Add 1 μl of primer and 1 μg of total RNA (RNA obtained in step 10) to a sterilized RNase-free microcentrifuge tube and add ddH2O to 13 μl.
[0170] 12) Heat at 70°C for 5 min to destroy RNA secondary structure;
[0171] 13) Place on ice immediately to prevent the secondary structure from reforming, then centrifuge briefly to the bottom of the tube;
[0172] 14) Add the following to the mixed sample of primers and template:
[0173] Table 11
[0174] Reagents Usage 5xRT Reaction Buffer 5μl Oligo 1μl dNTP Mix 1μl M-MLV Reverse Transcriptase 1μl <![CDATA[Add ddH2O to the total volume]]> 25μl
[0175] 15) Mix gently and keep warm at 50℃ for 30min;
[0176] 16) Heat at 85°C for 5 min and cool on ice to obtain cDNA;
[0177] 17) Prepare PCR reaction solution according to the following table (the reaction solution should be prepared on ice):
[0178] Table 12
[0179] Reagents Usage TB Green Premix Ex TaqⅡ(2x) 10μl Primer F (GAPDH-F, SOX2-F, NANOG-F, OCT4-F) 0.8μl Primer R (GAPDH-R, SOX2-R, NANOG-R, OCT4-R) 0.8μl DNA template (iPSC63, wild-type WT iPSC) 100ng Xμl Sterilized water Add to 20 μl
[0180] 18) Perform Real Time PCR reaction.
[0181] Using two-step PCR amplification, the standard procedure is as follows:
[0182] Table 13
[0183]
[0184] The results of rtPCR showed that the three pluripotency markers OCT4, SOX2 and NANOG, like the housekeeping gene GAPDH, all had normal expression of mRNA ( Fig.12 ).
[0185] (4) Identification of three germ layer differentiation
[0186] 1) Prepare two 10 cm culture dishes with cells at a cell volume of more than 80%, wash the cells twice with DPBS, and add 2 ml of ACCUTASE TM , digested at 37℃ for 3min, most of the cells fell off, and 4mL mTeSR TM 1 medium to terminate digestion, then collect the remaining cells with DPBS, transfer them to two 15mL centrifuge tubes respectively, centrifuge (200g, 4min), and remove the supernatant.
[0187] 2) Wash with DPBS, resuspend, and centrifuge (200 g, 4 min).
[0188] 3) Resuspend the cells in DMEM / F12 medium and count them to make the final cell concentration reach 1×10 7 cells / mL.
[0189] 4) Add 300ul of Matrigel to a 1.5ml EP tube, then add 300ul of cell suspension, and then add 0.6ul of Y-27632, mix gently (Matrigel is sticky, be careful not to blow out a lot of bubbles), and place on ice.
[0190] 5) Immunodeficient mice aged 1.5 to 2 months (about 25 g / mouse) were anesthetized by intraperitoneal injection of avertin. After the mice became soft, the hair on both sides of their backs were shaved.
[0191] 6) Before cell injection, centrifuge for a moment, then mix the cell suspension with a yellow pipette tip; then use a 1 ml syringe with the needle removed to draw up the suspension, and inject 250 μL of cell suspension subcutaneously on each side of the back of each mouse. Each tube of cells is injected into two points of a mouse, and a bulge can be observed during the injection process.
[0192] 7) After the injection, picric acid is used to mark the cell injection site to facilitate subsequent sampling.
[0193] 8) Observe the condition of the mice every week. After 2 weeks, begin to detect whether there is tumor formation at the injection site. If tumor formation is confirmed, remove the tumor, cut it in the middle, and fix it with fixative.
[0194] 9) After 48 hours of fixation, the tumor was sent to Guangzhou Sewell Biotechnology Co., Ltd. for paraffin embedding, sectioning and HE staining.
[0195] HE staining results showed that three different germ layer tissues were formed in the tumor (ref. Fig.13 ), indicating that iPSC63 has the ability to differentiate into three different germ layers in vivo.
[0196] The above sequencing results and verification of the pluripotency of the iPSC cell line proved that the iPSC cell line with ARHGAP11B gene deletion was successfully constructed.
[0197] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention. SEQUENCE LISTING <110> Wuyi University <120> A method for constructing an iPSC cell line with ARHGAP11B gene deletion and its application <130> 2022-02-24 <160> 28 <170> PatentIn version 3.5 <210> 1 <211> 554 <212> DNA <213> Nucleotide sequence of exon 6 of ARHGAP11B gene <400> 1 atccagtgag aataagatgg atagcagcaa tcttgcagta atatttgcac caaatcttct 60 tcagacaagt gaaggacatg aaaagatgtc ttctaacgca gaaaagaagg tacgattaca 120 ggctgcagta gtacagactc ttatcgatta tgcatcagat attggtaaga tgtagttgca 180 ttattaacag aatttgttta aatgaggaaa atctctgttt ctttcaaagg aactatgaag 240 gcaactgtta gaaagttggt atattactga cctcaccccc accctacagt accggcccct 300 cctgcaaaga aaaaaagaaa agaaattggt atattagtat ctaaacattt ttggggaaga 360 gtggaggaag gataataatt gtcttacttg tgaacatttt catttagggc gtgtaccaga 420 ctttatcctg gaaaagatac cagccatgtt gggtattgat ggtctctgtg ctactccatc 480 actggaaggc tttgaagaag gtgaatatga aactcctggt gaatataaga gaaagagaag 540 acaacgtgta ggag 554 <210> 2 <211> 20 <212> DNA <213> Nucleotide sequence of sgRNA1 <400> 2 gcgtgtacca gactttatcc 20 <210> 3 <211> 20 <212> DNA <213> Nucleotide sequence of sgRNA2 <400> 3 ggaaaagata ccagccatgt 20 <210> 4 <211> 20 <212> DNA <213> Nucleotide sequence of sgRNA3 <400> 4 gactttatcc tggaaaagat 20 <210> 5 <211> 20 <212> DNA <213> exon6-F <400> 5 atattactga cctcaccccc 20 <210> 6 <211> 20 <212> DNA <213> exon6-R <400> 6 ggtgcttaaa gcacagctgg 20 <210> 7 <211> 20 <212> DNA <213> EBNA1-F <400> 7 tgtctgacag cgaccatgaa 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 8<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> EBNA1-R<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 8<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> aaatacacca acagcacgca 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 9<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Primer1-F<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 9<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ggaggatgct acaaacaaag 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 10<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Primer1-R<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 10<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> cccaaaaaca tatgttcaca 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 11<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Primer2-F<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 11<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> aacaaagcta aattcaaggc 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 12<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Primer2-R<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 12<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> acaaaggatc acagcattat 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 13<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Primer3-F<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 13<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gattacagtg tgcctttcat 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 14<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 20<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Primer3-R<h2 style=";text-align:left;direction:ltr"> <400> 14 acacagttca gacaaaagcc 20 <210> 15 <211> 20 <212> DNA <213> Primer4-F <400> 15 gtcaagtcat gacaaatacg 20 <210> 16 <211> 20 <212> DNA <213> Primer4-R <400> 16 ggttatcaaa catgccaaac 20 <210> 17 <211> 20 <212> DNA <213> Primer5-F <400> 17 agatttcaat aagcaggctc 20 <210> 18 <211> 20 <212> DNA <213> Primer5-R <400> 18 aaaaagac acctggaaga 20 <210> 19 <211> 20 <212> DNA <213> Primer6-F <400> 19 tgctcttatt cttctccttc 20 <210> 20 <211> 20 <212> DNA <213> Primer6-R <400> 20 ttgcacctca ctaaacctga 20 <210> 21 <211> 20 <212> DNA <213> Primer7-F <400> 21 atgttagtat ctgtctccct 20 <210> 22 <211> 20 <212> DNA <213> Primer7-R <400> 22 aggaaccaca aaaccatgct 20 <210> 23 <211> 20 <212> DNA <213> Primer8-F <400> 23 gatgactgtc ttcttgctgt 20 <210> 24 <211> 20 <212> DNA <213> Primer8-R <400> 24 gccatgatta tcaacgtaga 20 <210> 25 <211> 20 <212> DNA <213> Primer9-F <400> 25 cctcagaaag tgacctattt 20 <210> 26 <211> 20 <212> DNA <213> Primer9-R <400> 26 atgcctcttc acatggcttt 20 <210> 27 <211> 20 <212> DNA <213> Primer10-F <400> 27 attaccgag tcttgggtat 20 <210> 28 <211> 20 <212> DNA <213> Primer10-R <400> 28 agtcaagttc tggtgaagat 20
Claims
1. A method for knocking out the ARHGAP11B gene in an iPSC cell line based on the CRISPR / Cas9 system, characterized in that: The following steps are involved: S1. Transfect iPSCs with CRISPR / Cas9 vectors, culture them, and screen the successfully transfected positive iPSCs with puromycin; S2. Identify the pluripotency of successfully transfected positive iPSCs; The CRISPR / Cas9 vector includes a specific sgRNA for targeted knockout of the human ARHGAP11B gene, a resistance gene Puro, and a GFP fluorescent protein gene; The targeting site of the sgRNA in the human ARHGAP11B gene is located on exon 6 of the human ARHGAP11B gene; the nucleotide sequence corresponding to the sgRNA is: a) sgRNA1: gcgtgtaccagactttatcc; and, b) sgRNA2: ggaaaagataccagccatgt; and, c) sgRNA3: gactttatcctggaaaagat.
2. The construction method according to claim 1, characterized in that: The transfection in step S1 is performed by electroporation using the BEX CUY2EDIT Ⅱ transfection system.
3. The construction method according to claim 1, characterized in that: After the transfection in step S1, iPSCs were added to the mTeSR containing Y-27632. TM 1 culture medium.
4. The construction method according to claim 1, characterized in that: The construction method further comprises the step of performing PCR identification on positive iPSCs, and the primers in the PCR identification are shown in SEQ ID NOs: 5-6.
